A comparative review of the isotretinoin pregnancy risk management programs across four continents
- PMID: 29508918
- DOI: 10.1111/ijd.13950
A comparative review of the isotretinoin pregnancy risk management programs across four continents
Abstract
Isotretinoin has revolutionized the treatment of severe acne vulgaris, a condition which if left untreated may result in significant socio-psychological implications for those affected. Timely access to isotretinoin therapy is important to avoid the risks of potential physical and emotional scarring. However, due to its high risks of teratogenicity, isotretinoin must be used with care in females of childbearing potential. Since isotretinoin's introduction, numerous risk management programs have been implemented across the world in an attempt to prevent isotretinoin use in pregnancy. This paper aims to provide an evidence-based review of the risk management programs for isotretinoin in Australia, Europe, Singapore, New Zealand, and the United States of America. The effectiveness of these programs and the factors leading to isotretinoin exposure in pregnancy are critically analyzed in an effort to inform the future direction with respect to designing the ideal regulatory program. Stringent risk management programs, such as the iPLEDGE in the US and Pregnancy Prevention Program (PPP) in Europe, may not be effective in reducing the risks of fetal exposure to isotretinoin when used alone. There is evidence that such strenuous regulation results in increased fear of teratogenic risks but does not translate into a reduced rate of pregnancies exposed to isotretinoin. A successful program must prioritize education about effective contraception, while minimizing any extraneous requirements, to ensure that women are not inadvertently undertreated for acne.
© 2018 The International Society of Dermatology.
Similar articles
-
What is the best approach to reducing birth defects associated with isotretinoin?PLoS Med. 2006 Nov;3(11):e483. doi: 10.1371/journal.pmed.0030483. PLoS Med. 2006. PMID: 17121451 Free PMC article. Review.
-
Isotretinoin: update on controversial issues.J Pediatr Adolesc Gynecol. 2013 Oct;26(5):290-3. doi: 10.1016/j.jpag.2013.05.007. J Pediatr Adolesc Gynecol. 2013. PMID: 24147278 Review.
-
Compliance with pregnancy prevention programmes of isotretinoin in Europe: a systematic review.Br J Dermatol. 2011 Feb;164(2):238-44. doi: 10.1111/j.1365-2133.2010.09976.x. Br J Dermatol. 2011. PMID: 20716214 Review.
-
We Pledge to Change iPLEDGE.JAMA Dermatol. 2015 Jul;151(7):701-2. doi: 10.1001/jamadermatol.2015.0736. JAMA Dermatol. 2015. PMID: 25853235 No abstract available.
-
Can we ensure the safe use of known human teratogens? Introduction of generic isotretinoin in the US as an example.Drug Saf. 2004;27(14):1069-80. doi: 10.2165/00002018-200427140-00001. Drug Saf. 2004. PMID: 15554743
Cited by
-
Non-compliance with pregnancy prevention recommendations for isotretinoin in Korea between 2019-2020.Obstet Gynecol Sci. 2021 Mar;64(2):201-208. doi: 10.5468/ogs.20247. Epub 2021 Jan 8. Obstet Gynecol Sci. 2021. PMID: 33752279 Free PMC article.
-
Compliance with the pregnancy prevention program among women initiating isotretinoin treatment between 2014 and 2021: A nationwide cohort study on the French Health Data System (SNDS).J Eur Acad Dermatol Venereol. 2025 Apr;39(4):806-814. doi: 10.1111/jdv.20073. Epub 2024 May 19. J Eur Acad Dermatol Venereol. 2025. PMID: 38764351 Free PMC article.
-
Contraceptive counseling for iPLEDGE and its burden on dermatologists.Arch Dermatol Res. 2024 May 28;316(6):287. doi: 10.1007/s00403-024-03070-5. Arch Dermatol Res. 2024. PMID: 38805059 Review.
-
Real-World Fetal Exposure to Acne Treatments in the United States: A Retrospective Analysis from 2006 to 2015.Drug Saf. 2021 Apr;44(4):447-454. doi: 10.1007/s40264-021-01053-3. Epub 2021 Mar 8. Drug Saf. 2021. PMID: 33683646 Free PMC article.
-
An Assessment of the Knowledge of Oral Isotretinoin (Roaccutane) Treatment Among Pharmacy Students in Saudi Arabia.Cureus. 2023 Jun 13;15(6):e40388. doi: 10.7759/cureus.40388. eCollection 2023 Jun. Cureus. 2023. PMID: 37456447 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical